Beiersdorf Aktiengesellschaft Stock Timeline

2026-08-03 — H1 2026 results

Group sales declined 3.5% organically to €4.95bn in the first half. Consumer sales fell 4.0% on an organic basis. EBIT excluding special factors reached €768m, with a margin of 15.5%. Management acknowledged ongoing pressure on NIVEA and maintained cautious near-term guidance, though continued to emphasize Derma strength [1][14].

Investor sentiment shifted toward a defensive posture. Derma emerged as the primary growth driver and structural counterweight to NIVEA's weakness. The market began pricing in a multi-quarter NIVEA rebalancing cycle rather than a near-term recovery. Share performance reflected this caution, trading sideways to lower from spring levels as investors awaited evidence of NIVEA stabilization [1][14].

2026-04-21 — Q1 2026 quarterly statement

Group organic sales contracted 4.6% in the first quarter, with Consumer down 4.7%. Management reiterated full-year guidance and flagged rebalancing initiatives for NIVEA [10][12].

The cautious tone reinforced investor perception of 2026 as an operational consolidation year. Derma demonstrated resilience while legacy NIVEA required repositioning and capital investment. Investor focus narrowed to product mix and margin performance rather than headline sales growth. Share trading showed a short-term downtrend punctuated by relief rallies tied to Derma updates or margin beats [10][12].

2026-03-02 — Full-year results for 2025

Group organic growth reached 2.4% for the full year, with Consumer organic growth at 2.5%. Derma recorded double-digit growth for the fifth consecutive year. EBIT margin excluding special factors rose to approximately 14.0%, and EPS excluding special factors increased [3][7].

The results reinforced the narrative of Beiersdorf as a resilient consumer staples compounder with Derma becoming an increasingly material high-growth segment. Investors responded positively to evidence of margin expansion and dividend stability, though near-term caution about NIVEA's mid-cycle variability persisted. Share performance rallied from 2025 H1 levels into early 2026 on the back of organic growth beats, then plateaued as 2026 guidance tempered expectations [3][7].

2025-04-17 — Annual General Meeting and dividend decision

The AGM approved a dividend of €1.00 per share for FY2024, an increase from the prior €0.70 level. The decision signaled management confidence in cash flow generation and a shareholder-friendly capital allocation approach [9][6].

The dividend increase supported a value and income-oriented investor base and reduced near-term downside concerns. Share performance steadied through 2025 as improved investor interest coincided with the dividend lift [9][6].

2024 — Derma outperformance and margin progression

FY2024 results showed group sales of approximately €9.45bn with operating margin expansion (EBIT margin excluding special factors trending from 13.4% toward 13.9% into 2025). Derma contribution increased while NIVEA underwent repositioning investment [7].

The results reinforced a longer-term thesis of portfolio rebalancing. Investors increasingly characterized Beiersdorf as a mid-single-digit sales grower with expanding margins driven by product mix and cost discipline. Some labeled it a defensive compounder with targeted upside if NIVEA revived. Share performance reflected this view, trending higher through much of 2024 into early 2025 [7].

2023 — Post-pandemic normalization and strategic Derma acceleration

2023 reporting emphasized normalization after pandemic distortions, margin recovery, and strategic acceleration of Derma brands. EPS and margin metrics showed year-on-year improvement [7].

Market perception shifted from cyclical recovery to structural portfolio reweighting. Management credibility improved as cost measures and brand investments translated to better profitability. Many investors began valuing the stock as a stable consumer compounder rather than a legacy brand holder. Share performance showed a gradual uptrend through 2023 with periodic pullbacks on macro headlines [7].

2022 — Inflation pressures and margin defense

2022 results reflected cost and raw-material inflation. Management implemented price increases and efficiency measures while organic growth resumed, though margins faced pressure in parts of the business [7].

Investor sentiment was mixed. Some viewed Beiersdorf as weathering inflation through pricing and mix; others questioned margin resilience and consumer recovery speed. Share performance remained rangebound to slightly recovery-oriented as markets digested inflation impacts and company mitigation steps [7].

2021 — Early recovery and dividend restoration

2021 showed recovery from COVID-19 troughs in certain channels. FY2021 EPS and dividend were restored to pre-shock levels at €0.70, and management communicated multi-year growth ambition and efficiency plans [7][6].

Investor perception remained mixed between recovery play and defensive staple. Brand strength was appreciated, though structural growth questions persisted beyond steady cash flows. The stock was often characterized as a value and dividend holding. Share performance reflected this, moving from 2020 lows into a consolidation range through 2021 [7][6].